Mine KAYMAKÇI, Ali ACAR, Metin ÇAPAR, Ayfer BALA, Cemalettin AKYÜREK

Medroksiprogesteron asetat ve dydrogesteronun rat endometriumu üzerine etkilerinin değerlendirilmesi

Amaç: Rat endometriumunda medroksiprogesteron asetat ve dydrogesteronun etkilerini karşılaştırmak. Yöntem: 28 adet Wistar cinsi dişi rat kullanıldı. Ratlar 3 gruba ayrıldı. A grubuna (10 rat) 20 gün 1mgr/gün oral medroksi progesteron asetat , B grubuna 20 gün 1mgr/gün oral dydrogesteron verildi. C grubuna ilaç verilmedi. 20 gün sonunda endometrium patolojik incelemeye tabii tutuldu. Bulgular: Her iki ilaç rat endometriumu üzerinde erken sekresyona sebep oldu. Sonuç: Dydrogesteron tabii progesteronun steroizomeridir. Medroksiprogesteron asetattan daha az yan etkiye sahiptir. Bu nedenle dydrogesteron, medroksiprogesteron asetat yerine kullanılabilinir.

Anahtar Kelimeler:

Sıçanlar, Karşılaştırmalı çalışma, Didrogesteron, Endometriyum, Patoloji, Medroksiprogesteron 17-asetat

Analysis of medroxyprogesterone acetate and dydrogesterone effects on rat endometrium

Objectives: To compare the effect of medroxyprogesterone acetate and dydrogesterone on rat endometrium. Method: 28 rats (species of wistar) were used in this study . Rats were divided into 3 groups.Group A (10 rats) was given 1 mg medroxyprogesterone acetate per day,group B (ten rats) was given 1 mg D per day orally for twenty days. Group C (8 rats) was not given any drug. At the end of twenty days,pathological examination of rat endometrium was done Results : If medroxyprogesterone acetate and dydrogesterone were given at the same dose for the same time interval , both drugs caused early secretory phase changes on rat endometrium. Conclusion: Dydrogesterone is the sterioisomer of natural progesterone,so it has less side effect than medroxyprogesterone. In conclusion dydrogesterone can be used instead of medroxyprogesterone acetate..

Keywords:

Rats, Comparative Study, Dydrogesterone, Endometrium, Pathology, Medroxyprogesterone 17-Acetate,

PDF

___

1. Kayaalp SO. Östrojenler, progestinler ve antagonistleri. İçinde: Rasyonel tedavi yönünden tıbbi farmakoloji 5. Baskı.Ankara: Feryal Matbaacılık, 1987;2765-83.
2. Speroff L, Glass RH, Kase NG. Clinical gynecologic endocrinology and infertilty. 5 th ed. Baltimore: Williams and Wilkins, 1994; 6:183-231
3. Leather A, Savas M, Studd J WW. Endometrial histology and bleeding patterns after 8 years of continuous combined oestrogen and progestagen therapy in postmenopausel women. Obstet Gynecol 1991;78:1008-10.
4. Adashi EY, Resnick CE, Jeffrey N, Packman BA, Hurwitz A, Palne WD. Cytokine mediated regülation of ovarian function: Tumor necrosis factor alpha inhibits gonadotrophin-supported progesterone accumulation by differentiating and luteinised murine granulosa cells. Am J Obstet Gynecol 1990; 162: 889-896.
5. King RYB, Whitehead MI. Assesment of the potency of orally administered progestins in women. Fertil Steril 1986; 46:106-65
6. Candron Y, Hendrickx B. Comparision of two aquine estrogen dydrogesterone regimens in the climacteric. Maturitas. 1988; 10: 133-41
7. Cullen KJ, Lipmann ME. Estrogen regulation of protein synthesis and cell growth in human breast cancer. Vit Horm 1989; 45:127-172
8. Bulun SE, Mahendroo MS, Simpson ER. Polymerase chain reaction amplification fails to detect aromatase cytochrome P450 transcriptis in normal human endometrium or decidua, J Clin Endoc Metab 1993; 76:1458-63
9. Zhang X, Mille BG. Some biological activities of cronolone and medroxyprogesterone acetate in the uterus of the sheep, mouse and rabbit. Reprod Fertil Dev 1989; 1:157-69.
10. Marshburn PB, Head JR, Mac Donald PC, Casey ML. Culture characteristics of human endometrial glandular epithelium throughout the menstrual cycle: Modulation of DNA synthesis by 17 beta-estradiol and MPA. Am J Obstet Gynecol 1992; 167:1888-98.
11. Ottoson UB, Johansson BG, Von Schoutz B. Subfractions of high-density lipoprotein cholesterol during estrogen replacement therapy. A comparison between progestagens and natural progesterone. Am J Obstet Gynecol 1985; 151: 746-50.
12. Cano A, Fernandes H, Serona S, Mahiques P. Effect of continuos oestradiol-medroxyprogesterone administration on plasma lipids and lipoproteins, Maturitas 1991; 13:35-38.
13. Weinstein L, Bewtra C, Gallagher JC. Evaluation of a continuos combined low-dose regimen of estrogen-progestin for treatment of the menopausel patient. Am J Obstet Gynecol 1990; 162:1534-42.
14. Van der Mooren MJ, Demacker PNM, Thomas CMG, Borm GF, Rolland R.Beneficial effects on serum lipoproteins by 17 beta oestradiol- dydrogesterone therapy in postmenapausel women a prospective study. Eur J Obstet Gynecol and Reprod Bio 1993; 52:117-123.
15. Burch DJ, Spowart KJM, Jesinger DK, Dandall S, Smith SK, A dose ranging study of the use of cyclical dydrogesterone with continuous 17 beta oestradiol. Br J Obstet Gynecol 1995; 102:243-248.
16. Hillard TC, Siddle NC, Fraser D, Whitehead MJ, Continuous combined conjugated equine, estrogen-progestagen therapy: Effects of MPA and norethindrone acetate on bleeding patterns and endometrial histologic diagnosis. Am J Obstet Gynecol 1992; 167:1-7
17. Lindahl B, Alm P, Fernö M, Norgren A. Endometrial hyperplasia: A prospective randomized study of histopatology, tissue steroid receptors and plasma steroids after curettage with or without high dose gestagen treatment. Anticancer Research 1990; 10:725-30.
18. Johnston WIH. Dydrogesterone and endometriosis. Br J Obstet Gynaecol 1976; 33:77-88.
19. Cornillie FJ, Puttemans P, Burosens IA. Histology and ultrastructure of human endometriotic tissues treated with dydrogesterone. Eur J Obstet Gynecol Reprod Biol 1987; 26:39-55.
20. Anthony A, Luciano R, Türksoy N, Carleo J. Evaluation of oral medroxyprogesterone acetate in treatment of endometriosis. Obstet Gynecol 1998; 72:323-27.
21. Colstone A, Kossy L, Parker RA. The impact of luteal phase deficiency in an infertile population. Am J Obstet Gynecol 1990; 162:937-45.
22. Karamardian LM, Grimes DA. Luteal phase deficiency: Effect of treatment of pregnancy rates. Am J Obstet Gynecol 1992; 167:1391-98.
23. Enrlich CE, Young PC, Cleary RF. Cytoplasmic progesterone and estradiol receptors in. normal, hyperplastic and carsinomatous endometrium: Theropeutic implications. Am J Obstet Gynecol 1981; 141:539-44.
24. Schatz F,Lockwood CJ. Progestin regülation plasminogen activator iInhibitor type 1 in primary cultures of endometrial stromal and decidual cells. Jour Clinic Endoc Metab. 1993; 77:621-625.
25. Lee RB, Burke TW, Park RC. Estrogen replacement therapy following treatment for stage 1 endometrial carcinoma. Gynecol Oncol 1991; 36:189-191.
26. Rodrique M, Zaino RJ, Satyaswaroop P. Designing a schedule of progestin administration in the control of endometrial carcinoma growth in the nude mouse model. Am J Obstet Gynecol 1996; 162:928-35.